Long-term Investing


Latest Special Reports


  • A research associate performs a buffer exchange for protein formulation at AMGEN, a drug research and development laboratory.

    Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.

  • Steven DeSanctis

    Steven DeSanctis, one of the most widely followed small-cap strategists on Wall Street, discusses his top investment themes in the space.

  • Sad, upset dog

    Credit Suisse downgrades J.M. Smucker, maker of Kibbles 'n Bits dog food and Milk-Bone treats, to neutral from outperform.